Does the media refer more to MTD or QGEN?

In the previous week, Mettler-Toledo International had 9 more articles in the media than Qiagen. MarketBeat recorded 10 mentions for Mettler-Toledo International and 1 mentions for Qiagen. Qiagen's average media sentiment score of 0.44 beat Mettler-Toledo International's score of 0.38 indicating that Qiagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mettler-Toledo International 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, RVTY or QGEN?

Qiagen has lower revenue, but higher earnings than Revvity. Qiagen is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Revvity $2.91B 5.91 $241.20M $2.10 73.43 Qiagen $2.09B 4.48 $424.88M $1.95 23.29

Is RVTY or QGEN more profitable?

Qiagen has a net margin of 19.49% compared to Revvity's net margin of 8.16%. Qiagen's return on equity of 14.47% beat Revvity's return on equity. Company Net Margins Return on Equity Return on Assets Revvity 8.16% 8.34% 5.01% Qiagen 19.49% 14.47% 8.34%

Does the media refer more to RVTY or QGEN?

In the previous week, Revvity had 4 more articles in the media than Qiagen. MarketBeat recorded 5 mentions for Revvity and 1 mentions for Qiagen. Revvity's average media sentiment score of 0.46 beat Qiagen's score of 0.44 indicating that Revvity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, QGEN or MEDP?

Medpace has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qiagen $2.09B 4.48 $424.88M $1.95 23.29 Medpace $2.53B 6.75 $451.12M $17.06 35.88

Is QGEN or MEDP more profitable?

Qiagen has a net margin of 19.49% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat Qiagen's return on equity. Company Net Margins Return on Equity Return on Assets Qiagen 19.49% 14.47% 8.34% Medpace 17.67% 110.15% 24.84%

Does the media favor QGEN or MEDP?

In the previous week, Medpace had 6 more articles in the media than Qiagen. MarketBeat recorded 7 mentions for Medpace and 1 mentions for Qiagen. Medpace's average media sentiment score of 0.68 beat Qiagen's score of 0.44 indicating that Medpace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Medpace 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ICLR or QGEN?

Qiagen has lower revenue, but higher earnings than Icon. Qiagen is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Icon $8.25B 1.52 $229.34M $4.26 38.54 Qiagen $2.09B 4.48 $424.88M $1.95 23.29

Is ICLR or QGEN more profitable?

Qiagen has a net margin of 19.49% compared to Icon's net margin of 3.99%. Qiagen's return on equity of 14.47% beat Icon's return on equity. Company Net Margins Return on Equity Return on Assets Icon 3.99% 8.02% 4.56% Qiagen 19.49% 14.47% 8.34%

Does the media favor ICLR or QGEN?

In the previous week, Icon had 7 more articles in the media than Qiagen. MarketBeat recorded 8 mentions for Icon and 1 mentions for Qiagen. Qiagen's average media sentiment score of 0.44 beat Icon's score of 0.24 indicating that Qiagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Icon 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Qiagen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Qiagen (QGEN) Competitors

$45.42 +0.89 (+2.01%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$45.40 -0.03 (-0.06%)

As of 10/9/2026 07:30 PM Eastern

Compare

QGEN vs. MTD, RVTY, MEDP, CRL, and ICLR

Should you buy Qiagen stock or one of its competitors? Qiagen's main competitors and comparable companies include Mettler-Toledo International (MTD), Revvity (RVTY), Medpace (MEDP), Charles River Laboratories International (CRL), and Icon (ICLR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Qiagen compare to Mettler-Toledo International?

Mettler-Toledo International (NYSE:MTD) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Mettler-Toledo International had 9 more articles in the media than Qiagen. MarketBeat recorded 10 mentions for Mettler-Toledo International and 1 mentions for Qiagen. Qiagen's average media sentiment score of 0.44 beat Mettler-Toledo International's score of 0.38 indicating that Qiagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mettler-Toledo International	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.1% of Mettler-Toledo International shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 0.7% of Mettler-Toledo International shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Mettler-Toledo International presently has a consensus price target of $1,459.54, suggesting a potential downside of 5.91%. Qiagen has a consensus price target of $43.51, suggesting a potential downside of 4.22%. Given Qiagen's stronger consensus rating and higher possible upside, analysts plainly believe Qiagen is more favorable than Mettler-Toledo International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mettler-Toledo International	1 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.27
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43

Mettler-Toledo International has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mettler-Toledo International	$4.03B	7.72	$869.19M	$44.43	34.91
Qiagen	$2.09B	4.48	$424.88M	$1.95	23.29

Mettler-Toledo International has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Mettler-Toledo International has a net margin of 21.91% compared to Qiagen's net margin of 19.49%. Qiagen's return on equity of 14.47% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mettler-Toledo International	21.91%	-1,212.14%	25.11%
Qiagen	19.49%	14.47%	8.34%

Summary

Mettler-Toledo International beats Qiagen on 11 of the 17 factors compared between the two stocks.

How does Qiagen compare to Revvity?

Revvity (NYSE:RVTY) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

86.7% of Revvity shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 0.9% of Revvity shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Revvity pays an annual dividend of $0.28 per share and has a dividend yield of 0.2%. Qiagen pays an annual dividend of $0.35 per share and has a dividend yield of 0.8%. Revvity pays out 13.3% of its earnings in the form of a dividend. Qiagen pays out 17.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Revvity has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

Qiagen has a net margin of 19.49% compared to Revvity's net margin of 8.16%. Qiagen's return on equity of 14.47% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.16%	8.34%	5.01%
Qiagen	19.49%	14.47%	8.34%

In the previous week, Revvity had 4 more articles in the media than Qiagen. MarketBeat recorded 5 mentions for Revvity and 1 mentions for Qiagen. Revvity's average media sentiment score of 0.46 beat Qiagen's score of 0.44 indicating that Revvity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Revvity currently has a consensus price target of $120.50, suggesting a potential downside of 21.86%. Qiagen has a consensus price target of $43.51, suggesting a potential downside of 4.22%. Given Qiagen's stronger consensus rating and higher probable upside, analysts plainly believe Qiagen is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0 Sell rating(s)	14 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.26
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43

Qiagen has lower revenue, but higher earnings than Revvity. Qiagen is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.91B	5.91	$241.20M	$2.10	73.43
Qiagen	$2.09B	4.48	$424.88M	$1.95	23.29

Summary

Revvity beats Qiagen on 10 of the 19 factors compared between the two stocks.

How does Qiagen compare to Medpace?

Qiagen (NYSE:QGEN) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Qiagen currently has a consensus target price of $43.51, suggesting a potential downside of 4.22%. Medpace has a consensus target price of $607.73, suggesting a potential downside of 0.71%. Given Medpace's higher probable upside, analysts plainly believe Medpace is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43
Medpace	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.23

Qiagen has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Medpace has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market.

In the previous week, Medpace had 6 more articles in the media than Qiagen. MarketBeat recorded 7 mentions for Medpace and 1 mentions for Qiagen. Medpace's average media sentiment score of 0.68 beat Qiagen's score of 0.44 indicating that Medpace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Medpace	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has higher revenue and earnings than Qiagen. Qiagen is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	4.48	$424.88M	$1.95	23.29
Medpace	$2.53B	6.75	$451.12M	$17.06	35.88

70.0% of Qiagen shares are held by institutional investors. Comparatively, 78.0% of Medpace shares are held by institutional investors. 9.0% of Qiagen shares are held by company insiders. Comparatively, 20.5% of Medpace shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Qiagen has a net margin of 19.49% compared to Medpace's net margin of 17.67%. Medpace's return on equity of 110.15% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.49%	14.47%	8.34%
Medpace	17.67%	110.15%	24.84%

Summary

Medpace beats Qiagen on 13 of the 17 factors compared between the two stocks.

How does Qiagen compare to Charles River Laboratories International?

Charles River Laboratories International (NYSE:CRL) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Qiagen has a net margin of 19.49% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Qiagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Charles River Laboratories International	-5.96%	15.75%	6.51%
Qiagen	19.49%	14.47%	8.34%

Charles River Laboratories International has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

98.9% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Qiagen has lower revenue, but higher earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Charles River Laboratories International	$4.02B	3.59	-$144.34M	-$4.85	N/A
Qiagen	$2.09B	4.48	$424.88M	$1.95	23.29

In the previous week, Charles River Laboratories International had 22 more articles in the media than Qiagen. MarketBeat recorded 23 mentions for Charles River Laboratories International and 1 mentions for Qiagen. Charles River Laboratories International's average media sentiment score of 0.68 beat Qiagen's score of 0.44 indicating that Charles River Laboratories International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Charles River Laboratories International	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Charles River Laboratories International presently has a consensus target price of $300.11, indicating a potential downside of 0.70%. Qiagen has a consensus target price of $43.51, indicating a potential downside of 4.22%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, equities analysts clearly believe Charles River Laboratories International is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Charles River Laboratories International	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.88
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43

Summary

Charles River Laboratories International beats Qiagen on 10 of the 17 factors compared between the two stocks.

How does Qiagen compare to Icon?

Icon (NASDAQ:ICLR) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

In the previous week, Icon had 7 more articles in the media than Qiagen. MarketBeat recorded 8 mentions for Icon and 1 mentions for Qiagen. Qiagen's average media sentiment score of 0.44 beat Icon's score of 0.24 indicating that Qiagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Icon	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Qiagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Qiagen has lower revenue, but higher earnings than Icon. Qiagen is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.25B	1.52	$229.34M	$4.26	38.54
Qiagen	$2.09B	4.48	$424.88M	$1.95	23.29

Icon has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Qiagen has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Qiagen has a net margin of 19.49% compared to Icon's net margin of 3.99%. Qiagen's return on equity of 14.47% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Icon	3.99%	8.02%	4.56%
Qiagen	19.49%	14.47%	8.34%

Icon currently has a consensus target price of $174.73, indicating a potential upside of 6.43%. Qiagen has a consensus target price of $43.51, indicating a potential downside of 4.22%. Given Icon's stronger consensus rating and higher possible upside, equities analysts clearly believe Icon is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	1 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
Qiagen	0 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.43

95.6% of Icon shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 44.0% of Icon shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Icon beats Qiagen on 10 of the 16 factors compared between the two stocks.

Get Qiagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QGEN vs. The Competition

Export

Metric	Qiagen	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$9.35B	$10.44B	$7.16B	$22.94B
Dividend Yield	0.77%	1.45%	2.53%	3.72%
P/E Ratio	18.74	32.42	275.30	28.60
Price / Sales	4.48	106.86	635.99	14.93
Price / Cash	13.33	27.23	76.38	37.72
Price / Book	2.54	6.48	11.22	4.72
Net Income	$424.88M	$56.67B	$3.50B	$1.07B
7 Day Performance	1.53%	-1.01%	-0.89%	0.35%
1 Month Performance	7.91%	8.89%	-4.42%	-2.94%
1 Year Performance	-8.05%	32.14%	7.03%	9.25%

Qiagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QGEN Qiagen	2.6797 of 5 stars	$45.42 +2.0%	$43.51 -4.2%	-8.2%	$9.35B	$2.09B	18.74	5,654
MTD Mettler-Toledo International	2.6653 of 5 stars	$1,542.12 +3.8%	$1,446.36 -6.2%	+18.6%	$29.78B	$4.03B	34.71	18,100	News Coverage Analyst Forecast
RVTY Revvity	2.4941 of 5 stars	$157.14 +3.7%	$116.57 -25.8%	+68.3%	$16.91B	$2.86B	74.83	11,000	Analyst Forecast
MEDP Medpace	2.7183 of 5 stars	$620.51 +3.5%	$602.27 -2.9%	+18.0%	$16.73B	$2.78B	36.37	6,200	Analyst Forecast
CRL Charles River Laboratories International	2.3228 of 5 stars	$310.84 +7.1%	$300.11 -3.5%	+75.6%	$13.85B	$4.02B	N/A	19,700	Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:QGEN) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Qiagen (QGEN) Competitors

QGEN vs. MTD, RVTY, MEDP, CRL, and ICLR

How does Qiagen compare to Mettler-Toledo International?

Summary

How does Qiagen compare to Revvity?

Summary

How does Qiagen compare to Medpace?

Summary

How does Qiagen compare to Charles River Laboratories International?

Summary

How does Qiagen compare to Icon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QGEN vs. The Competition

Qiagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Qiagen (QGEN) Competitors

QGEN vs. MTD, RVTY, MEDP, CRL, and ICLR

How does Qiagen compare to Mettler-Toledo International?

Does the media refer more to MTD or QGEN?

Do institutionals and insiders have more ownership in MTD or QGEN?

Do analysts prefer MTD or QGEN?

Which has higher valuation & earnings, MTD or QGEN?

Which has more risk & volatility, MTD or QGEN?

Is MTD or QGEN more profitable?

Summary

How does Qiagen compare to Revvity?

Do insiders and institutionals have more ownership in RVTY or QGEN?

Is RVTY or QGEN a better dividend stock?

Which has more risk & volatility, RVTY or QGEN?

Is RVTY or QGEN more profitable?

Does the media refer more to RVTY or QGEN?

Do analysts rate RVTY or QGEN?

Which has better earnings and valuation, RVTY or QGEN?

Summary

How does Qiagen compare to Medpace?

Do analysts prefer QGEN or MEDP?

Which has more volatility and risk, QGEN or MEDP?

Does the media favor QGEN or MEDP?

Which has higher valuation and earnings, QGEN or MEDP?

Do insiders & institutionals have more ownership in QGEN or MEDP?

Is QGEN or MEDP more profitable?

Summary

How does Qiagen compare to Charles River Laboratories International?

Is CRL or QGEN more profitable?

Which has more risk and volatility, CRL or QGEN?

Do institutionals & insiders believe in CRL or QGEN?

Which has higher earnings & valuation, CRL or QGEN?

Does the media refer more to CRL or QGEN?

Do analysts rate CRL or QGEN?

Summary

How does Qiagen compare to Icon?

Does the media favor ICLR or QGEN?

Which has higher valuation and earnings, ICLR or QGEN?

Which has more risk & volatility, ICLR or QGEN?

Is ICLR or QGEN more profitable?

Do analysts rate ICLR or QGEN?

Do insiders and institutionals have more ownership in ICLR or QGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QGEN vs. The Competition

Qiagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools